Selected article for: "cell proliferation and study objective"
Title: Research Communications of the 24th ECVIM-CA Congress
  • Document date: 2015_1_10
    • ID: r59usk02_180
    Snippet: Some of the authors are members of diagnostic laboratories (PennGen). Supported in part by the NIH OD #010939. Glucagon-like peptide-1 (GLP-1)is a gastrointestinal hormone released in response to food intake that increases insulin secretion, inhibits glucagon secretion, slows gastric emptying and induces satiation. It is also assumed to stimulate beta-cell proliferation. GLP-1 agonists are successfully used in humans with type 2 diabetes mellitus.....
    Document: Some of the authors are members of diagnostic laboratories (PennGen). Supported in part by the NIH OD #010939. Glucagon-like peptide-1 (GLP-1)is a gastrointestinal hormone released in response to food intake that increases insulin secretion, inhibits glucagon secretion, slows gastric emptying and induces satiation. It is also assumed to stimulate beta-cell proliferation. GLP-1 agonists are successfully used in humans with type 2 diabetes mellitus usually either in combination with insulin or other anti-diabetic drugs. In healthy cats twice daily (exenatide) as well as once weekly (exenatide extended-release (ER)) application of GLP-1 agonists induced pronounced insulin secretion. Benefits of exenatide ER are the regimen of once weekly injection and less side effects. The objective of the study was to assess whether administration of exenatide ER in addition to standard treatment leads to improved glycemic control and higher remission rates in cats with newly diagnosed diabetes.

    Search related documents:
    Co phrase search for related documents
    • beta cell and study objective: 1, 2, 3
    • diagnostic laboratory and study objective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • diagnostic laboratory and successfully human: 1
    • food intake and study objective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • glycemic control and study objective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • insulin secretion and study objective: 1, 2, 3
    • remission rate and study objective: 1, 2
    • standard treatment addition and study objective: 1, 2, 3
    • standard treatment and study objective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25